1. Home
  2. CRBU vs ENLV Comparison

CRBU vs ENLV Comparison

Compare CRBU & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.59

Market Cap

166.6M

Sector

Health Care

ML Signal

HOLD

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$4.20

Market Cap

149.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBU
ENLV
Founded
2011
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.6M
149.0M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
CRBU
ENLV
Price
$1.59
$4.20
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$10.75
$20.00
AVG Volume (30 Days)
2.4M
280.7K
Earning Date
05-08-2026
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
3.64
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.63
N/A
Revenue Next Year
$10.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.38
$0.43
52 Week High
$3.53
$7.64

Technical Indicators

Market Signals
Indicator
CRBU
ENLV
Relative Strength Index (RSI) 35.14 57.84
Support Level $1.39 $0.79
Resistance Level $1.73 $7.64
Average True Range (ATR) 0.11 0.59
MACD -0.01 -0.09
Stochastic Oscillator 0.94 50.64

Price Performance

Historical Comparison
CRBU
ENLV

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Share on Social Networks: